Compare Gemini Space Station Inc (GEMI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Summit Therapeutics Inc — how do they compare? Gemini Space Station Inc trades at $4.61 (market cap $590.44M), while Summit Therapeutics Inc trades at $13.89 (market cap $11.70B). The key difference: Summit Therapeutics Inc is far larger — about 19.8× Gemini Space Station Inc's market cap. Which is the better fit depends on your goals.
| GEMI | SMMT | |
|---|---|---|
Market Cap | $590.44M | $11.70B |
Sector | Technology | Health |
52-Week High | $32.52 | $29.32 |
52-Week Low | $3.91 | $13.05 |
Enterprise Value | $580.43M | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.69, up 8.06% in the past 24 hours, with a bullish technical signal but weak fundamentals. The company reported a net loss of $582.81 million in 2025 on $179.57 million revenue, with negative profit margins and cash burn from operations. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May-July 2026.
Outlook remains challenged by persistent losses and legal risks, though analyst consensus suggests modest upside to a $5.88 price target. Investment opportunity hinges on execution turnaround, but high operational and litigation risks warrant caution for stock investors.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
